Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Aimmune Therapeutics : Nestle Completes Acquisition of Aimmune Therapeutics

10/15/2020 | 08:23am EDT

Nestle announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT).

Joining Nestle Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestle Health Science company, it will manage NHSc's global pharmaceutical business.

'Nestle Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support healthier lives,' said Greg Behar, CEO of NHSc. 'Aimmune's PALFORZIA, the first medication approved for treating peanut allergy, is a game-changer and it's only the beginning. Aimmune's pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally.'

Aimmune will continue to be run from Brisbane, California. Andrew Oxtoby has been named as Aimmune's President & CEO, along with a new executive leadership team. Oxtoby was previously Aimmune's Chief Commercial Officer.

The development program for Aimmune-which consists of the potential use of PALFORZIA in toddlers and adults, multiple clinical development programs in other allergies, and the development of the monoclonal antibody AlMab7195 will proceed as planned.

PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as an oral immunotherapy for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy. In Europe, Aimmune's marketing authorization application for AR101 is under review with the European Medicines Agency (EMA), with a decision anticipated in 2020. A Swiss Agency for Therapeutic Products (SwissMedic) review of AR101 also is ongoing, with a decision expected in 2021.

The previously announced tender offer for all of the outstanding shares of Aimmune common stock, other than shares held by Nestle and its affiliates, for a price of US$34.50 per share in cash expired as scheduled at midnight, Eastern Time, on October 9, 2020. The minimum tender condition and all of the other conditions to the offer were satisfied and on October 13, 2020, Nestle through a wholly owned subsidiary (Purchaser), accepted for payment all shares validly tendered and not properly withdrawn.

Following its acceptance of the tendered shares, Nestle caused Purchaser to merge with Aimmune. As a result of the merger, all Aimmune shares not purchased in the tender offer (other than (i) shares owned by Nestle or Purchaser, (ii) shares held by Aimmune and (iii) shares as to which the holder thereof has properly exercised appraisal rights under Delaware law) were converted into the right to receive the same US$34.50 per share in cash (without interest and subject to applicable withholding taxes) that would have been paid had such shares been purchased in the tender offer. Aimmune common stock has ceased to be traded on the NASDAQ Global Market.

About Nestle Health Science

Nestle Health Science (NHSc), a globally managed business unit of Nestle, is a recognized leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. NHSc is redefining the way we approach the management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world who are committed to making a difference in people's lives, for a healthier today and tomorrow.

About Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.


Christoph Meier

Tel: +41 21 924 2200

Email: mediarelations@nestle.com

(C) 2020 Electronic News Publishing, source ENP Newswire

02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
01/22AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
01/05AIMMUNE THERAPEUTICS  : European Commission approves first treatment for peanut ..
2020AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
2020AIMMUNE THERAPEUTICS  : European Commission Approves Aimmune's PALFORZIA® as Fir..
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
2020AIMMUNE THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement, Co..
2020AIMMUNE THERAPEUTICS  : Receives Positive CHMP Opinion on PALFORZIA for the Trea..
2020MONTEVERDE & ASSOCIATES PC  : Files Class Action Lawsuit On Behalf Of Shareholde..
2020AIMMUNE THERAPEUTICS  : Nestle Completes Acquisition of Aimmune Therapeutics
More news
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
Stacey Denenberg Seltzer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615